Ian Roberts (Chief Technology Officer) and Karine Proulx (Drug Discovery Alliance Manager) from Healx, a bioinformatics company focused on drug discovery, provide an insight into how Healx’s artificial intelligence (AI) technology can be used to accelerate the generation of treatments for rare diseases. With the recent launch of the Rare Treatment Accelerator programme, designed to speed up the in silico to clinical trial phase for the development of repurposed treatments, Karine describes how patient groups can apply to collaborate with Healx on repurposing projects. Details on the application process can be found on Healx’s website here.